Optimer Pharmaceuticals, Inc. (OPTR) Message Board
-
ECONOMIC STUDY (for jla...)
since the COST of Dificid was such a stumbling block in your mind, I hope today's release of economic data & benefit will help you loosen your grip on vanco as first-line treatment. The argument, which never addressed recurrences, no longer holds water...with this data I believe the hospitals and insurance companies (including the Medicare program) will conclude that the cost of using Dificid vs. vanco is financially justified. Then again, maybe you've embarked on your own economic benefit analysis and would like to share.
http://finance.yahoo.com/news/Data-Suggest-Optimer-DIFICID-prnews-527041725.html?x=0-
I saw the data well before it was presented. There are 2 major flaws with the data. (1) Ananlysis used Wholesale Acquisition Price (WAC) for analysis. Hospitals do not pay WAC pricing. Hospitals pay GPO negotiated pricing (2)Vancomycin economic analysis did not use Generic Vancomycin pricing which is dirt cheap. If you used Vancocin pricing as the comparator pricing, of course there is savings with Dificid. The devil is in the detail. I give OPTR credit for their effort in pumping up OPTR stock price with this "news".
- 4 Replies to jiarealty
-
c'mon, you and proinvestor (term used loosely, of course) must be hurtin' today, after last week's pounding.
-
shooting it down. Still in the waiting room preparing your next presentation?
-
You knew the study results before they were released??? Well we knew what the study results were going to be before the idea of doing a study was broached!!!!
-
I would advise you to short the stock (if you have money of course).
That would be the best solution otherwise you look pathetic.
Nothing personal.
-